Mounjaro Beats Wegovy in Weight Loss Study
Breakthrough research shows Mounjaro users lost significantly more weight than Wegovy patients in head-to-head comparison, potentially reshaping obesity treatment across the UK.
Breakthrough research shows Mounjaro users lost significantly more weight than Wegovy patients in head-to-head comparison, potentially reshaping obesity treatment across the UK.
A woman's astonishing account reveals how dramatic weight loss transformed her social experience, exposing society's hidden bias toward thinner bodies and raising questions about 'pretty privilege'.
The NHS is poised to prescribe diabetes medication Mounjaro for weight loss in a groundbreaking move that could help millions of Britons struggling with obesity. Health Secretary Wes Streeting announces major expansion of weight management services.
Eli Lilly accuses the UK of having Europe's most challenging drug pricing system, threatening patient access to new medicines like Mounjaro amid ongoing NHS negotiations.
Exclusive investigation reveals the soaring financial and human cost of new obesity drugs. As millions rely on Wegovy and Ozempic, the NHS faces a multi-billion pound dilemma when patients stop treatment and weight returns.
A major UK trial reveals the new semaglutide pill, a potential game-changer in obesity treatment, leads to significant weight loss, offering a powerful alternative to injections.
Exclusive: Carly Stokes, a mother battling severe obesity, is denied access to the 'game-changer' drug Tirzepatide (Mounjaro) on the NHS despite its proven success, sparking outrage and a debate on healthcare funding.
A landmark UK study reveals the new weight loss injection Tirzepatide is significantly more effective than existing treatments, helping patients lose over 20% of their body weight and offering new hope in the fight against obesity.
Breakthrough obesity drug Orforglipron shows unprecedented results in clinical trials, reducing body weight by a fifth and offering new hope for millions struggling with weight management in the UK.
A landmark study presented in Vienna shows the diabetes drug tirzepatide (Mounjaro) leads to unprecedented weight loss in NHS patients, offering new hope in the fight against obesity.
New research reveals that GLP-1 weight-loss injections not only aid in shedding pounds but also significantly quiet intrusive thoughts about food, offering a dual benefit for patients.
Groundbreaking NHS research reveals obesity injections like Wegovy are dramatically more effective than lifestyle changes alone for teenagers, offering new hope in the childhood obesity crisis.
Exclusive investigation reveals stark regional disparities in NHS breast cancer care across England, with patients facing unacceptable treatment delays and fragmented services despite government promises.
The NHS is rolling out a powerful new 4mg weekly injection of semaglutide, a 'game-changer' in weight loss treatment, as part of a major strategy to tackle the nation's obesity epidemic.
The NHS receives a powerful new weapon in the fight against obesity as medical regulators approve a higher 2.4mg dose of Wegovy, proven to help patients shed significantly more weight.
Exclusive investigation reveals the alarming trend of unregulated weight-loss jabs like Retatrutide being promoted on TikTok, posing severe health risks to UK users desperate for quick fixes.
The NHS Sussex integrated care board has been escalated to 'tier 2' oversight following a review that uncovered significant failings in its leadership and culture, raising serious concerns for health services across Brighton and East Sussex.
A landmark UNICEF report reveals a historic shift: ultra-processed foods have led to more children globally being obese than underweight for the first time, signalling a urgent public health crisis.
Exclusive: The NHS is now prescribing powerful diabetes medications Ozempic and Mounjaro for weight loss, sparking a massive surge in demand and a fierce debate over ethics and supply.
A UK mother's revelation that she uses her disability benefits to pay for weight-loss jabs like Wegovy has ignited a fierce national debate on welfare spending, medical ethics, and obesity treatment.
Exclusive: The UK government faces imminent NHS strike escalation as unions vow to combat plans replacing striking staff with outsourced workers, potentially prolonging the largest walkout in health service history.
An NHS administrator reveals how she lost four stone using a controversial cost-cutting method to obtain diabetes drug Mounjaro for weight loss, as doctors issue serious safety warnings.
The NHS in England is set to provide the highly effective Mounjaro (tirzepatide) weight-loss injection, hailed as a major breakthrough in fighting obesity and related diseases like type 2 diabetes.
The NHS is dramatically expanding the availability of prescription weight-loss injections, hailed as a 'game-changer' in treating obesity. This major rollout could benefit hundreds of thousands more patients across England.
Shadow Health Secretary Wes Streeting delivers a stark diagnosis of the NHS, labelling it 'broken' and vowing a fundamental transformation to save the cherished institution from collapse.
UK researchers are exploring a revolutionary 'microdosing' strategy for powerful weight-loss medications like Wegovy, potentially slashing costs and side effects while boosting accessibility for NHS patients.
Exclusive investigation reveals the UK towns drowning in fast food, with Jaywick, Essex, crowned the nation's takeaway capital. Health experts sound the alarm on obesity crisis.
Exclusive investigation reveals the staggering postcode lottery and soaring costs of life-changing obesity drugs like Mounjaro and Wegovy, as the NHS struggles to cope with unprecedented demand.
Groundbreaking UK study reveals a new diabetes medication, Mounjaro (tirzepatide), achieves significantly greater weight loss and superior cardiovascular benefits compared to Ozempic, revolutionising obesity treatment.
Former Culture Minister Ed Vaizey calls for VAT removal on prescription obesity drugs, arguing it would boost public health and reduce long-term NHS costs.